At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 453 enrolled
Drug / intervention
ABBV-8E12 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating ABBV-8E12 and placebo for ABBV-8E12 for Alzheimer's Disease. Completed, enrolled 453 participants across 68 sites in 11 countries.
Detailed Summary
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesAustralia, Belgium, Canada, Denmark, Finland, Italy, Netherlands, New Zealand, Spain, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartJan 2017
Primary CompletionMar 2021
Study CompletionJul 2021
TodayJul 2026
First PostedAug 26, 2016
Enrollment StartJan 26, 2017
Primary CompletionMar 30, 2021
Study CompletionJul 28, 2021
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 9.8 years ago
Interventions
ABBV-8E12drug
ABBV-8E12 solution for IV infusion
placebo for ABBV-8E12drug
placebo solution for intravenous (IV) infusion